Sunesis Pharmaceuticals (FRA:RYIS) EV-to-EBIT : -3.44 (As of May. 12, 2024)

Sunesis Pharmaceuticals EV-to-EBIT Chart

Sunesis Pharmaceuticals Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
EV-to-EBIT		Get a 7-Day Free Trial					-7.05	-12.90	-2.72	-5.29	-5.23

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
EV-to-EBIT	Get a 7-Day Free Trial															-5.29	-6.82	-4.45	-2.72	-5.23

Competitive Comparison of Sunesis Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Sunesis Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunesis Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's EV-to-EBIT falls into.

Sunesis Pharmaceuticals EV-to-EBIT Calculation

Sunesis Pharmaceuticals's EV-to-EBIT for today is calculated as:

Sunesis Pharmaceuticals's current Enterprise Value is €63.71 Mil.
Sunesis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-18.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunesis Pharmaceuticals  (FRA:RYIS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sunesis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 is calculated as:

Sunesis Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2020 was €82.71 Mil.
Sunesis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-18.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunesis Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description